

IN THE CLAIMS:

- 1-6. (Canceled)
7. (New) A method for improving neuropathic pain which comprises systemically administering to a subject a compound having mGluR1 antagonistic activity and having no activity on Group II and Group III of metabotropic glutamate in an amount effective for improving neuropathic pain.
8. (New) The method according to claim 7, wherein the neuropathic pain is induced by diabetes or compression of nerves.
9. (New) The method according to claim 8, wherein the neuropathic pain is induced by diabetes.
10. (New) The method according to claim 7, wherein the systemic administration method is oral administration.
11. (New) The method according to claim 7, wherein the compound having mGluR1 antagonistic activity and having no activity on Group II and Group III of metabotropic glutamate is a compound selected from 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-

PRELIMINARY AMENDMENT
Divisional of Application No.: 10/031,404

Attorney Docket No.: Q75942

a]benzimidazole-2-carboxamide dihydrochloride and (+)-(1*R*,2*S*)-6-amino-N-methyl-N-(2-methylcyclohexyl)thiazolo[3,2-a]benzimidazole-2-carboxamide dihydrochloride.